The control research of escitalopram vs venlafaxine XR.on the treatment of generalized anxiety disorder

Abstract

Abstract: AIM: To observe the efficacy and safety of escitalopram and venlafaxine on the treatment of generalized anxiety disorder(GAD) patients. METHODS: 74 patients who met the ICD-10 criteria for GAD were divided into escitalopram group(n=38) and venlafaxine group(n=36) randomly. The trial lasted 8 weeks. The anxiety status and efficacy was evaluated with HAMA at the baseline, 1^st, 2^th, 4^th and 8^th weekend respectively while the depression status was evaluated by HAMD,and the safety was evaluated by TESS and laboratory examination.RESULTS: The HAMA scores of both group declined significantly by the end of 1st week(P<0.01), and the reduction of HAMA scores in the escitalopram group were larger than those in venlafaxine group at the end of 1^st, 2^th and 4^th weekend(P<0.05), while there were no significant difference between the two groups at the end of 8^th weekend(P>0.05). There were significant difference within the remission rate 60.5% vs 66.7%, and response rate 78.9% vs 86.1% between the two groups(P<0.01). The HAMD scores decreased significantly after 8 weeks treatment in both groups(P<0.01). The side effects of both groups had no significant difference(P>0.05). CONCLUSION: Either escitalopram or venlafaxine would be effective for GAD, but it seemed that venlafaxine was more effective than escitalopram, and escitalopram responses faster, while the safety was similar.

Key words: Escitalopram, Venlafaxine, Generalized anxiety disorder

CLC Number:

R749.7

SHEN Zhong-xia, GUAN Tie-feng, SHEN Xing-hua, QIAN Ming-cai, LIN Min, YANG Jian-hong. The control research of escitalopram vs venlafaxine XR.on the treatment of generalized anxiety disorder[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1167-1171.

References

[1] 吴文源. 焦虑障碍防治指南[M]. 北京:人民卫生出版社,2010:115.
[2] Kessler RC, Berglund P, Demler O, et al.Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication[J]. Arch Gen Psychiatry,2005, 62(6): 593-602.
[3] Ma X, Xiang YT, Cai ZJ, Generalized anxiety disorder in China: prevalence, sociodemographic correlates, comorbidity, and suicide attempts[J].Perspect Psychiatr Care , 2009,45(2):119-127.
[4] Davidson JR,Zhang W,Connor KM,et al.A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)[J].J Psychopharmacol,2008,10(2):1-24.
[5] 吴文源. 焦虑障碍防治指南[M]. 北京:人民卫生出版社,2010:129.
[6] Goodman WK, Bose A, Wang Q, et al.Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials[J]. J Affect Disord,2005,87(2/3):161-167.
[7] Allgulander C, Hackett D, Salinas E .Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study[J]. Br J Psychiatry,2001, 179:15-22.
[8] Davideson JR, Bose A, Kozotzer A, et al.Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled,flexible-dose study[J]. Depress Anxiety, 2004,19(4):234-240.
[9] Gelenberg AJ, Lydiard RB, Rudolph RL, et al.Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial[J]. JAMA ,2000,283: 3082-3088.
[10] 张燕,李功迎,李陨丹,等. 万拉法辛缓释剂与帕罗西汀治疗广泛性焦虑障碍的对照研究[J].中南药学,2009,7(11):150-153.
[11] 李良,杨剑虹,沈鑫华,等.艾司西酞普兰与西酞普兰治疗广泛性焦虑的对照研究[J].上海精神医学,2007,19(6):360-361.
[12] Montgomery SA,Sheehan DV,Meoni P,et al.Characterization of the longitudinal course of improvement ingeneralized anxiety disorder during long-term treatment with venlafaxine XR[J].J Psychiatr Res,2002,36(4):209-217.
[13] Bose A, Korotzer A, Gommoll C, et al, Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder[J]. Depress Anxiety,2008,25(10):854-861.
[14] 司天梅,舒良.关于新抗抑郁药艾司西酞普兰[J].临床精神医学杂志,2007,17(2):68-69.
[15] Chen FH,Larsen MB,Sanchezc,et al.The Senantiomer 0f R,Scitalopram,increases inhibitor binding to the human serotonin transporter by an allosteric mechanism.Comparison with other serotonin transporteR inhibitors[J].Eur Neuropsychopharmacology,2005,15(7):193-198.
[16] Boyer P, Mahé V, Hackett D.Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release[J]. Eur Psychiatry , 2004,19(5) :272-279.
[17] Kennedy SH,Andersen HF,Lam RW.Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR:a meta-anal-ysis[J].J Psychiatry Neurosci,2006,31(2):122-131.
[18] Silverstone PH, Studnitz E, Buller R.Current therapeutic strategies for anxious depressives[J]. Expert Rev Neurother, 2003,3(2):193-201.